Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 2, 2011

Primary Completion Date

October 18, 2011

Study Completion Date

October 18, 2011

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Brodalumab

Administered intravenously once every 4 weeks

Trial Locations (34)

2820

Research Site, Bonheiden

3000

Research Site, Leuven

3065

Research Site, Fitzroy

3128

Research Site, Box Hill

5037

Research Site, Kurralta Park

6160

Research Site, Fremantle

8800

Research Site, Roeselare

9000

Research Site, Ghent

11021

Research Site, Great Neck

20815

Research Site, Chevy Chase

28207

Research Site, Charlotte

31059

Research Site, Toulouse

32256

Research Site, Jacksonville

35294

Research Site, Birmingham

36164

Research Site, Pontevedra

37203

Research Site, Nashville

54511

Research Site, Vandœuvre-lès-Nancy

55905

Research Site, Rochester

59037

Research Site, Lille

65265

Research Site, Mexico

70403

Research Site, Hammond

75010

Research Site, Paris

75571

Research Site, Paris

78229

Research Site, San Antonio

84405

Research Site, Ogden

V6Z 2K5

Research Site, Vancouver

R3A 1R9

Research Site, Winnipeg

L8S 4J9

Research Site, Hamilton

H3A 1A1

Research Site, Montreal

06202

Research Site, Nice

1081 HV

Research Site, Amsterdam

85-021

Research Site, Bydgoszcz

81-757

Research Site, Sopot

08036

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY